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Glucose transporter type 1 (GLUT1) deficiency syn-
drome (GLUT1-DS) leads to a wide range of neurologi-
cal symptoms. Ketogenic diets are very efficient to
control epilepsy and movement disorders. We tested a
novel simple and rapid blood test in 30 patients with
GLUT1-DS with predominant movement disorders, 18
patients with movement disorders attributed to other
genetic defects, and 346 healthy controls. We
detected significantly reduced GLUT1 expression only
on red blood cells from patients with GLUT1-DS (23
patients; 78%), including patients with inconclusive
genetic analysis. This test opens perspectives for the
screening of GLUT1-DS in children and adults with
cognitive impairment, movement disorder, or epilepsy.
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Glucose transporter type 1 (GLUT1) deficiency syn-drome (GLUT1-DS) is caused by impaired glucose
transport across the blood–brain barrier and into astro-
cytes attributed to heterozygous, likely mostly de novo,
mutations in the SLC2A1 gene encoding the glucose
transporter, GLUT1.1 GLUT1 is a membrane-bound
glycoprotein expressed in erythrocytes, brain microvessels,
and glial cells. SLC2A1 mutations limit brain glucose
availability and lead to cerebral energy deficiency. As a
consequence, GLUT1-DS manifests with a wide range of
neurological symptoms, including cognitive impairment,
epilepsy, and permanent and/or paroxysmal motor disor-
ders that usually start in early childhood.1,2 Early detec-
tion of GLUT1-DS is critical given that the disease is
treatable with ketogenic diets3 and, possibly, novel exper-
imental therapies.4,5
Any neuropediatrician or neurologist can encounter
patients with GLUT1-DS. Its diagnosis is, however, chal-
lenging because of the great heterogeneity of symptoms
and ages at onset. Besides the classical severe infantile-
onset epileptic encephalopathy, adult-onset forms have
been described with epilepsy or paroxysmal movement
disorders as the sole manifestations.6 The 3-O-methyl-D-
glucose (OMG) uptake assay is an important functional
measure of glucose transport across the red blood cell
(RBC) membrane,7 but is not available on a clinical basis
because it implies the use of radioactivity and precautions
in blood sample storage and preanalytical steps.8 In a
patient whose phenotype suggests GLUT1-DS, the diag-
nosis thus relies on lumbar puncture (LP)—that is, low
cerebrospinal fluid (CSF) glucose concentration, sup-
ported by low CSF lactate—and SLC2A1 molecular anal-
ysis. These approaches have some limitations. LP must
be performed after at least 6 hours of fasting, is invasive,
and runs the risk of complications.9 Moreover, an
unequivocal cutoff has not been set to date for CSF glu-
cose, with an heterogeneity in current practice although
the most used value is 2.2mM.8 On the other hand, the
analysis of the coding regions of SLC2A1 can be tedious,
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inconclusive in case of variants of unknown significance,
or may fail at identifying variants despite a very sugges-
tive clinical and biochemical phenotype.10
A minimally invasive and rapid diagnostic test for
GLUT1-DS, readily available in clinical practice, would
be an invaluable tool for the early detection of GLUT1-
DS. Here, we tested a novel diagnostic test on RBCs,
using flow cytometry, on a series of consecutive GLUT1
deficient patients with predominant movement disorders,
compared to patients with movement disorders attributed
to other genetic defects and healthy controls.
Study Population and Methods
Patients and Controls
We enrolled 30 patients (2–50 years old, 17 males/13
females) with GLUT1-DS presenting with a highly sug-
gestive clinical phenotype comprising variable degree of
developmental delay, movement disorders, and epilepsy
(Table), associated with low glucose CSF concentration
(2.0mM6 0.3), and/or a pathogenic SLC2A1 mutation
(see Table). CSF lactate concentration was available for
16 patients (see Table) and was consistently low
(0.9mM6 0.2), except for 1 patient (P20). Because the
majority of our GLUT1-DS patients manifested paroxys-
mal movement disorders, we also enrolled 18 patients
(11–73 years old, 12 males/6 females) with paroxysmal
movement disorders attributed to other genetic defects—
that is, mutations in ATP1A3, ADCY5, or PRRT2—to
determine whether the RBC test was able to distinguish
them among GLUT1-DS patients. All participants or
their caregivers provided written informed consent for
study procedures and data reporting. The study was
approved by the local ethics committee (CPPIdF6, La
Pitie-Salpe^trie`re University Hospital). The French
National Blood Service (Etablissement Franc¸ais du Sang)
provided blood samples from healthy donors.
CSF Glucose Concentration
CSF glucose was measured after a fasting period of at
least 6 hours using glucose hexokinase methodology.
SLC2A1 Molecular Analysis
Mutational analysis of all exons and intron-exon bound-
aries of the SLC2A1 gene were performed on genomic
DNA from patients and their parents by direct Sanger
sequencing (primer sequences are available upon request).
The GenBank [NM_006516] sequence was used as the
reference. Pathogenicity was predicted by in silico analy-
sis with Alamut Visual version 2.7 (Interactive Biosoft-
ware, Rouen, France). When no point mutation was
found, a single or multiple exon deletion or duplication
was searched by multiple ligation-dependent probe
amplification with SALSA MLPA KIT P138 SLC2A1
(MRC-Holland, BV, Amsterdam, Netherlands).1
Flow Cytometry Analysis of GLUT1 Surface
Expression on Circulating RBCs
At least 0.5ml of nonfasted venous blood was collected on
ethylenediaminetetraacetic acid (EDTA) tubes and kept at
4 8C for maximum 7 days before analysis. Whole blood
was diluted at 1/3,000 into phosphate-buffered saline
(PBS) containing 0.09% sodium azide, 1mM of EDTA,
and 0.33mg/ml of bovine serum albumin (binding buffer).
Approximately 80,000 RBCs per sample were transferred
into a 96-well microplate and stained with GLUT1.RBD
ligand fused to enhanced green fluorescent protein (eGFP;
METAFORA Biosystems, Evry, France) at 37 8C for 20
minutes.11,12 RBCs were washed twice with PBS and
resuspended in binding buffer. Acquisition was performed
on a FACSVerse flow cytometer (BD Biosciences, Franklin
Lakes, NJ) equipped with 405-, 488-, and 640-nm lasers.
Data analysis was performed using Flowjo software
(TreeStar, Inc., Ashland, OR). Debris and doublets were
excluded from the analysis; eGFP signal was collected for
each sample, by taking into account geometric mean of
gated, GLUT1.RBD-stained RBC. Results were available
within 24 hours upon sample reception.
Results
Our series reflects the wide range of phenotypes, ages, and
ages at onset in GLUT1-DS—that is, classical early-onset
severe encephalopathy, global developmental delay with
dystonia and epilepsy, early-onset absence epilepsy with
cognitive impairment, adult-onset movement disorders.
CSF glucose was measured in 25 of 30 patients because, in
two families, only molecular analysis was performed (P11,
P13, and P24) once the diagnosis was made in the index
case (P12, P25). Twenty of these 25 GLUT1-DS patients
(80%) exhibited a typical low CSF glucose (2.2mM).
The remaining 5 patients with CSF glucose between 2.3
and 2.5mM harbored either known pathogenic SCL2A1
mutations or novel de novo mutations.
Surface GLUT1 expression level on circulating
RBCs was performed blinded from the disease condition
in terms of symptoms, biochemistry, and genetics and
compared between GLUT1-DS patients, patients with
other genetic defects, and healthy donors. Most patients
were analyzed at least twice, with several-month intervals,
and the results were consistent for each patient, showing
the stability of GLUT1 deficiency on RBCs. A thorough
repeatability and reproducibility study was also per-
formed between two labs, supporting the robustness of
the RBC test (Fig 1). A distribution fitting of a normal
law to the series of data allowed describing the variability
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of GLUT1 expression level both in the normal popula-
tion and among patients (Fig 2). GLUT1 expression on
RBCs varied in healthy donors in a limit of 1.5 standard
deviations (SDs), corresponding in this population to
15% of change of GLUT1 compared to the mean sam-
ple. None of the patients bearing mutations in ATP1A3,
TABLE. Main Clinical, Biochemical, and Molecular Characteristics of Patients With GLUT1 Deficiency
Patient Sex Age Age at
Onset
LD Motor
Symptoms
Epilepsy Paroxysmal
Dyskinesia
CSF
Glucose
CSF
Lactate
RBC
Test
Mutation
P1 M 9y 2y 1 A — 11 1.9 1.1 100 p.Gly314Ser
P2 F 21y 6m 1 D — 11 2.0 Nd 66 p.Met1Thr
P3 F 25y 3m 1 A,D AA 11 2.0 0.9 109 p.Gly130Ser
P4 M 19y 2.5y 1 A,D AA 11 2.4 1.3 110 p.Thr295Met
P5 M 2y 9m 1 — AA — 1.8 1.1 41 p.Gly286Hisfs*94
P6 M 5y 6m 111 D S 1 1.7 0.9 60 del 1p34.2-p34.1
P7 F 4y 2y 111 A, D S 11 1.5 1.0 53 p.Lys183Glnfs*54
P8 F 26y 1.5y 1 A — 11 2.2 0.7 51 p.Ser294Pro
P9 F 22y 1y 1 A, D — 11 2.2 Nd 59 p.Met142Lys
P10 F 17y 6m 111 A GE — 2.2 0.7 62 p.Ser313Thrfs*23
P11 M 50y 14y — D AA 11 Nd Nd 52 p.Leu12Phe
P12 M 18y 2.5y 1 A — 11 2.2 Nd 61 p.Leu12Phe
P13 M 16y 2.5y 1 A, D — 1 Nd Nd 66 p.Leu12Phe
P14 M 3y 3m 11 A S 11 1.4 Nd 52 p.Met96Cysfs*2
P15 M 15y 9m 11 A — 11 2.3 1.1 54 p.Gly18Arg
P16 M 14y 1.5y 1 A S 11 1.9 0.7 63 not found
P17 M 6y 3m 111 D GE — 1.5 1.2 75 large del (1.97 Mb)
P18 F 29y 3m 111 A, D, S AA — 1.9 0.6 54 p.Gln282*
P19 F 4y 3m 1 A, D AA 11 1.9 0.9 86 p.Ala275Thr
P20 F 20y 1.5y — — GE 11 2.5 1.8 106 p.Gly314Ser
P21 F 18y 8y 1 — AA — 2.3 Nd 70 p.Val328Leu
P22 M 13y 3y 1 A, D 11 1.8 0.9 97 p.Thr310Asn
P23 M 25y 1.5y 1 D AA 11 2.4 Nd 45 p.Arg153Cys
P24 F 25y 5y — — AA 1 Nd Nd 88 p.Ala275Thr
P25 M 16y 4y 1 — S 11 2.2 Nd 77 p.Ala275Thr
P26 M 13y 1m 111 — S — 1.7 1.0 57 p.Glu41*
P27 F 10y 1.5y 11 D AA 1 1.5 Nd 54 not found
P28 M 13y 6m 11 A, D S 1 1.8 Nd 44 p.Arg126Cys
P29 F 18y 19m 11 — AA 11 Nd Nd 60 p.Ser324Leu
P30 M 50y 6y — — AA 1 Nd Nd 76 p.Ser324Leu
Age at onset refers to the first noticeable motor or cognitive symptom.
LD5 learning disability; CSF5 cerebrospinal fluid; RBC test5 red blood cell test (expressed as % of mean of healthy controls; normal values are
indicated in italics); M5male; F5 female; y5 year; m5month; A5 ataxia; D5 dystonia; AA5 atypical absence; GE5 generalized epilepsy;
S5 seizures; n5 normal;15mild;115moderate;1115 severe; —5 none; Nd5 not done.
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ADCY5, or PRRT2 had a reduced GLUT1 expression on
RBC (91–118% compared to healthy controls).
The RBC test identified 23 GLUT1-DS patients of
30 (78%) with at least 20% decrease (23–59% decrease)
of GLUT1 expression and no overlap between their
group and the controls (Fig 2). The RBC test did not
correlate with CSF glucose, nor age or age at onset.
Three GLUT1-DS patients were detected with this new
test despite a CSF glucose concentration >2.2mM
(Table, P15–21–23). Two patients with a clinical pheno-
type very suggestive of GLUT1-DS, and low CSF glu-
cose and lactate, but no SLC2A1 mutation had an abnor-
mal RBC test (Table 1, P16–27), thus further
confirming the diagnosis of GLUT1-DS. An OMG
uptake assay was previously performed on P16’s RBCs
and showed 63% of normal uptake, consistent with the
63% GLUT1 expression on RBCs measured here. Con-
versely, 1 patient presenting with a severe nonepileptic
encephalopathy, low CSF glucose (2.2mM), and a frame-
shift mutation in exon 10 (p.Gly471Glufs*37), but
inconclusive familial segregation, exhibited a normal
RBC test (data not shown) supporting that he does not
have GLUT1-DS. Seven GLUT1-DS patients displayed
normal GLUT1 expression on RBCs (Fig 2) and mainly
carried SLC2A1 mutations in exons 6 and 7. Two muta-
tions (P3 Gly130Ser and P4 Thr295Met) have been
reported in the literature, but were accompanied by a
mild decrease in OMG uptake compared to most muta-
tions—75% of normal uptake versus 50% meanwhile.13
Two mutations (P19-24 p.Ala275Thr and P1-P20
p.Gly314Ser) were shown to affect glucose uptake, but
only in Xenopus oocytes.14
FIGURE 1: (A) Repeatability: GLUT1-DS patient P26 was analyzed 12 times along with a healthy control, in the same experi-
ment. Standard deviations are shown, which translate into CVs below 2.5%, pointing out the test’s high repeatability. (B,C,D)
Reproducibility: GLUT1-DS patient P26 was analyzed along with 5 healthy control samples. Experiment was repeated three
times (3 days) by three operators in two distinct labs. Mean GLUT1 expression and standard deviations are plotted for each
sample and each operator. Results were highly correlated between operators (all R2>0.98). No significant difference was
found between days, operators, nor labs; results were highly reproducible (Levene’s test; all p values,>0.93). CVs5 coefficients
of variation; GLUT15glucose transporter type 1; GLUT1-DS5glucose transporter type 1 deficiency syndrome.
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Discussion
This proof-of-concept study shows that GLUT1-DS can be
accurately detected through a minimally invasive and rapid
(24 hours) diagnostic test. We have been able to define the
physiological variation of GLUT1 expression level at the
surface of RBCs in the general population, and can con-
clude that plus or minus 15% GLUT1 expression change
fell within the physiological range, whereas more than 20%
decrease is a hallmark of GLUT1 deficiency related to
SLC2A1 mutations. Currently, the diagnostic rate of this
new test is comparable to CSF glucose and promises to be
more specific. Indeed, in a large series of 109 patients sus-
pected of GLUT1-DS with low CSF glucose and lactate,
only 68% displayed abnormal OMG uptake and 64% har-
bored a pathogenic SCL2A1 mutation.7 Furthermore, the
RBC test should be more cost-effective as compared to LP
and genetics, and the result comes back in less than 3 days
in current clinical practice. It has been designed so as to be
automated from sample preparation to data analysis, and is
CE (“Conformite Europeene” [“European Conformity”])
marked opening easy diffusion in central testing labs.
The RBC test was able to detect GLUT1-DS
patients regardless of their age and disease severity,
including 3 patients with CSF glucose concentration
>2.2mM, but known pathogenic SCL2A1 mutations
and/or de novo mutations. The detection of GLUT1
deficiency on RBCs in 2 patients presenting with a very
suggestive clinical and biochemical phenotype, but with-
out SLC2A1 exonic mutation suggests that this assay
should identify GLUT1-DS patients with mutations in
introns or regulating regions. Conversely, patients not
detected by the RBC test may correspond either to
patients with mutations affecting mildly glucose uptake,
as shown for four mutations13,14 harbored by 6 of the 7
patients with a normal RBC test, but not GLUT1
expression, or a brain-restricted GLUT1 deficiency, possi-
bly attributed to alterations of specific SLC2A1 isoforms.
Quantifying GLUT1 at the RBC surface opens
new perspectives for GLUT1-DS, especially to avoid cur-
rent considerable diagnosis delays. It is a major issue in
light of the great phenotypic variability and availability
of efficient treatments. Although more studies are
required to establish the diagnostic gain of the RBC test
on a larger cohort, such a simple diagnostic test, readily
available in clinical practice, ought to greatly enlarge the
screening of GLUT1-DS in any patient, child, or adult,
presenting with cognitive impairment, epilepsy, ataxia
and/or dystonia, or paroxysmal movement disorder.
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